In a report released today, George Zavoico from B.Riley FBR maintained a Buy rating on BioLife Solutions (NASDAQ: BLFS), with a price target of $22. The company’s shares closed yesterday at $16.51.
According to TipRanks.com, Zavoico is a 3-star analyst with an average return of 5.0% and a 49.4% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Catalyst Biosciences Inc, and Actinium Pharmaceuticals.
BioLife Solutions has an analyst consensus of Strong Buy, with a price target consensus of $22.33, which is a 35.3% upside from current levels. In a report issued on October 1, Maxim Group also maintained a Buy rating on the stock with a $26 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.35 and a one-year low of $4.63. Currently, BioLife Solutions has an average volume of 367.9K.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioLife Solutions, Inc. engages in the development, manufacture, and marketing of portfolio of biopreservation tools for cells, tissues, and organs including proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media. Its products include CryoStor, BloodStor, HypoThermosol FRS, and Cell Thawing Media.
